Nuclear Regulation RedHill Biopharma Completes Oral Opaganib Phase 2/3 COVID-19 Study Recruitment – Johnson City Press (Subscription) By Carmen Lillard On Jun 7, 2021 Share RedHill Biopharma Completes Oral Opaganib Phase 2/3 COVID-19 Trial Registration Johnson City Press (Subscription) BiopharmaCitycompletesCOVID19JohnsonOpaganiboralPhase Share
Comments are closed.